Effects of ACE inhibitors other than blood pressure (BP) reduction (such as improved endothelial function, bradykinin‐mediated vasodilatation and endothelial NO release, and change in extracellular matrix) are physiologically very suited to the proposed BPD pathophysiology. This evidence concerns the gene ACE and bronchopulmonary dysplasia.